




The Open COVID Journal

Content list available at: <https://opencovidjournal.com>



REVIEW ARTICLE

The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19

Abdallah S. Abdelsattar^{1,2}, Zahraa M. El-Awadly³, Mai Abdelgawad⁴, Fayrouz Mahmoud³, Sahar A. Allam⁵ and Mohamed A. Helal^{3,6,*}

¹Center for Microbiology and Phage Therapy, Zewail City of Science and Technology, October Gardens, 6th of October City, Giza, 12578, Egypt

²Center for X-Ray and Determination of Structure of Matter, Zewail City of Science and Technology, October Gardens, 6th of October, Giza, 12578, Egypt

³Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, 12587, Egypt

⁴Department of Biotechnology and Life Sciences, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, Beni-Suef, 62511, Egypt

⁵Faculty of Medicine, Tanta University, Tanta, 31512, Egypt

⁶Department of Medicinal Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt

Abstract:

The COVID-19 pandemic first appeared in Wuhan, China, in December 2019 in a cluster of pneumonia patients. The causative agent was found to be SARS-CoV-2. Here, we are summarizing current treatment strategies and highlighting the role of bioinformatics, molecular modeling, and structural biology during the COVID-19 pandemic. There are different pharmacological treatments, mostly repurposed drugs, employed for the treatment of COVID-19, including antiviral drugs, corticosteroids, biologic drugs, antibiotics, antifungal agents, and anticoagulants. Some immune-based therapies are also under evaluation, including convalescent plasma, IL-1, IL-6 inhibitors, and interferons. Different bioinformatics networks are established to provide information about the structure, transcriptome, and pathogenicity of the virus. The genotyping analysis for SARS-CoV-2 is also useful in identifying different mutations, SNPs, and conservative domains along the viral genome. Cryo-EM and X-ray diffraction had a crucial role in determining the structure of viral proteins such as spike (S) protein, main protease, and RdRp. NMR had a minor role and determining the structure of nucleocapsid (N) protein only. Several docking studies were performed to predict the interaction of certain FDA-approved drugs with known efficacy and toxicity, while others used natural products. Among different study types, *in silico* drug prediction and repurposing have the lowest risk with less off-target results. Therefore, bioinformatics and *in silico* studies have an important role during pandemics in providing information about viral structure and function and predicting potential treatments.

Keywords: SARS-CoV-2, Drug repurposing, Bioinformatics, Docking, Immune-based therapy, X-ray diffraction.

Article History

Received: March 09, 2021

Revised: July 28, 2021

Accepted: August 25, 2021

1. INTRODUCTION

1.1. The Appearance, Structure, and Origin of SARS-CoV-2

The world is recently facing Coronavirus Disease (COVID-19) that threatens public health everywhere. COVID-19 first appeared in Wuhan, China December 2019 in a cluster of pneumonia patients [1]. It was pronounced a global pandemic disease by the World Health Organization (WHO) on March 11th, 2020. The causative agent of COVID-19 belongs to RNA β - Coronaviruses. It has a 79.5% similarity with the genome of the Severe Acute Respiratory Syndrome Corona-

virus (SARS-CoV) that caused an outbreak during 2002-2003 [2]. The new virus also utilizes the angiotensin-converting enzyme 2 (ACE2) receptor for human cell entry [2]. WHO named the new virus SARS-CoV-2. It is an enveloped, positive-sense RNA, a single-stranded virus with a non-segmented genome. The viral genome of SARS-CoV-2 is very similar to that of other coronaviruses. It contains different numbers of open reading frames (ORFs), with two-thirds of the viral genome located in the first one (ORF1a/b) encoding 16 non-structural proteins (Nsps). The rest of the ORFs encodes the accessory and structural proteins, including envelope (E), membrane (M), nucleocapsid (N), and spike (S) glycoprotein [3 - 5].

S protein is considered the essential structural protein of the COVID-19 virus. It mediates the viral binding to the human

* Address correspondence to this author at the Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, 12587, Egypt; E-mail: mhelal@zewailcity.edu.eg

ACE2 receptor to facilitate the viral invasion into host cells. Inside the host cell, the S protein is cleaved by a host cell protease into S1 and S2 subunits. The S1 subunit mediates the interaction with hACE2, while the S2 subunit mediates the membrane fusion process [6, 7]. Binding of the Receptor Binding Domain (RBD) of the S1 subunit to hACE-2 receptor mediates the interaction of the heptad repeat 1 (HR1) and 2 (HR2) domains in its S2 subunit to make a six-helix bundle (6-HB) fusion core, bringing cellular and viral membranes in contact to facilitate infection [8]. The binding affinity of SARS-CoV-2 to ACE2 receptor is 10 to 20 times higher than SARS-CoV, which may be due to the presence of a distinct motif within the S1/S2 junction region responsible for viral fusion [7, 9]. Genome sequencing results and evolutionary analysis show that SARS-CoV-2 has 96.2% genomic similarity to Bat CoV RaTG1 virus. Therefore, bats are suspected to be the potential origin of the virus, which was transmitted later to humans by an unknown intermediate host [2], probably pangolins [10, 11].

1.2. Disease Transmission, Diagnosis, and Mortality Risk

The known route of transmission of the disease is respiratory droplets of patients while coughing or sneezing. The virus can also spread by contact with surfaces contaminated with the virus [12]. Virus transmission through feces was also recently reported [13]. The SARS-CoV-2 incubation period varies between 1 to 14 days [12], and the mean incubation period is 5.2 days [14].

The clinical characteristics of COVID-19 patients include fever which is the main symptom, dry cough, shortness of breath, fatigue, dyspnea, sore throat, and gastrointestinal symptoms such as vomiting, diarrhea, and nausea [15 - 17]. GI symptoms are not very common [16]. In most cases, the disease is mild with flu-like symptoms (80.9%). Severe cases requiring ICU administration represent 13.8%, while asymptomatic cases represent only about 1.2%, and they are usually children under 10 years [18]. Disease outcomes include respiratory failure, which is the major reason for death among patients (53%), circulatory failure, shock, fulminant myocarditis, acute respiratory distress syndrome (ARDS), renal complications such as AKI (75.4%), proteinuria, hematuria, multiple organ dysfunction, and death [16, 17, 19 - 21]. COVID-19 diagnosis is based on the detection of SARS-CoV-2 nucleic acids by RT-PCR in nasopharyngeal specimens [21]. Other critical laboratory measures for disease progression indication include white blood cells count, C-reactive protein

(CRP), D-dimers, procalcitonin (PCT), LDH, and lactate levels [22]. Chest CT and X-ray Imaging on COVID-19 patients is also essential for disease diagnosis and prediction of its progression. Images show bilateral or unilateral pneumonia [23] and peripheral interstitial changes with different small patches of shadows in the early stages [21, 24]. In severe cases, chest images can show bilateral multiple ground-glass opacity, infiltrating shadows, and pulmonary consolidation, accompanied by infrequent pleural effusion [15, 21, 25].

To date, the reported susceptibility factors and fatal disease outcomes predictors include age [26, 27], chronic diseases such as diabetes [25, 28], cardiovascular diseases [18], hypertension [25, 29], cancer [30], chronic respiratory disease [18], and lifestyle habits such as obesity and smoking [31]. Viral load and viral-shedding period are also important predictors for disease severity and fetal outcomes among different age groups [32].

2. USING OLD DRUGS TO TREAT NEW DISEASES

Various pharmacological treatments have been employed for repurposing and are set to an evaluation in clinical trials to treat COVID-19, targeting various proteins in different phases of the viral life cycle. Some were already evaluated in randomized controlled trials (RCTs), while others still need adequate testing. In fact, repurposing aids in rapidly discovering treatments in a pandemic spread owing to their well-established safety profile [33]. Some of these drugs were excluded due to observed ineffectiveness, safety concerns in COVID-19 patients, or both, whereas some others showed auspicious results. Table 1 summarizes the repurposed drugs for COVID-19 treatment and their target proteins. The fact that 79.5% of the proteins encoded in the SARS-CoV-2 are genetically similar to those of other SAR-CoVs makes the previous drugs used for their treatment, in addition to broad-spectrum antivirals, possible for repurposing [34]. The pharmacological agents belong to (1) Antiviral drug classes like (a) Nucleoside analogues that target the RNA dependent RNA polymerase (RdRp), (b) HIV protease inhibitors, (c) Neuraminidase inhibitors; (2) Corticosteroids; (3) Biologic drugs like Tocilizumab and Sarilumab; (4) Antibiotic and antifungal agents that should only be used in cases like high procalcitonin, hospital-acquired pneumonia, ventilator acquired pneumonia and pneumocystis pneumonia; (5) Anticoagulants; (6) Fresh frozen plasma; (7) Other potential treatments including drugs blocking the renin-angiotensin system (RAS) are still under investigation [35].

Table 1. Repurposed drugs for COVID-19 treatment with their target proteins, their original clinical use, and the software used.

Repurposed Drug	Target Protein in SARS-CoV-2	PDB Code of the Crystal Structure and Resolution	Original Clinical Purpose	Discovery	Software Used	References
Protease Inhibitors						
Lopinavir	Main protease	6Y2F Resolution: 1.95 Å	HIV	Molecular docking	IDentif.AI, DL (MT-DTI), ML (NLP, and NB), and AutoDock Vina	[49]

Repurposed Drug	Target Protein in SARS-CoV-2	PDB Code of the Crystal Structure and Resolution	Original Clinical Purpose	Discovery	Software Used	References
Ritonavir	Main Protease	6Y2F Resolution: 1.95 Å	HIV	Molecular docking	IDentif.AI, DL (MT-DTI), ML (NLP, and NB), and AutoDock Vina	[49]
TMC-310911	TMPRSS2/ 3C-Like proteinase	6LU7 Resolution: 2.16 Å	HIV-1	Docking-based virtual screening, molecular docking, and dynamics	PyRx 0.8	[49]
Camostat Mesylate	TMPRSS2	7MEQ Resolution: 1.95 Å	Serine protease inhibitor	Molecular Dynamics simulation and Markov modeling	PyEMMA 2	[48]
Nafamostat	TMPRSS2	7MEQ Resolution: 1.95 Å	Serine protease inhibitor	Molecular Dynamics	PyEMMA 2	[48]
Faldaprevir	3C-Like proteinase	6LU7 Resolution: 2.16 Å	HCV	Docking-based virtual screening, molecular docking, and dynamics	Surflex-dock and Autodock Vina	[43]
Aclarubicin	3C-Like proteinase	6LU7 Resolution: 2.16 Å	Cancer drug with multiple mechanisms of action	Docking-based virtual screening, molecular docking, and dynamics	Surflex-dock and Autodock Vina	[38]
Saquinavir	3C-Like proteinase	6LU7 Resolution: 2.16 Å	HIV	Docking-based virtual screening, molecular docking, and dynamics	Surflex-dock and Autodock Vina	[38]
Neuramidase Inhibitors						
Zanamivir	3C-Like proteinase	6LU7 Resolution: 2.16 Å	Influenza A & B	Molecular docking-based virtual screening & Homology modeling	Schrodinger®	[52]
Peramivir	3C-like proteinase	6LU7 Resolution: 2.16 Å	Influenza	Molecular docking and Molecular dynamics	Molecular Operating Environment (MOE) & GROMACS	[52]
Oseltamivir	3C-like proteinase	6LU7 Resolution: 2.16 Å	Influenza A & B	Molecular docking and Molecular dynamics	Molecular Operating Environment (MOE) & GROMACS	[53]
Nucleoside Analogue						
Favipiravir	RdRP	6L4R Resolution: 2.147 Å	Influenza	Molecular docking & structural modeling	AutoDock Vina & MODELLER 9.23	[36]
Galidesivir	RdRP	6L4R Resolution: 2.147 Å	HCV	Molecular docking	Autodock Vina	[38]
N4-Hydroxycytidine	3C-like protease	6LU7 Resolution: 2.16 Å	Broad-spectrum antiviral	Molecular docking	Autodock Vina, GOLD	[40]
Remdesivir	3C-like protease	6LU7 Resolution: 2.16 Å	Broad-spectrum antiviral	Molecular docking	IDentif.AI, DL (MT-DTI), ML (NLP), and AutoDock Vina	[36]
Ribavirin	RdRP	6L4R Resolution: 2.147 Å	RSV and HCV	Molecular docking	Autodock Vina	[37]
Triazavirin	Main Protease	6Y2F Resolution: 1.95 Å	Broad-spectrum antiviral	Molecular docking and molecular dynamics	Autodock Vina & MMGBSA approach	[39]
EIDD-2801	RdRP	6L4R Resolution: 2.147 Å	Influenza Virus	Docking-based virtual screening, molecular docking and dynamics	Guassian 16	[40]

2.1. Repurposing of Antiviral Drugs

2.1.1. Nucleoside Analogues

The nucleoside analogues repurposed for COVID-19 are

analogues for either guanine, adenosine, or cytidine, and they all target RdRp aiming to block the viral RNA synthesis. The drugs tested in RCTs and non-RCTs are Remdesivir, Favipiravir, Galidesivir, Ribavirin, Triazavirin, GS-44124, N4-

Hydroxycytidine, and its prodrug EIDD-2801 [36 - 42]. The tested drugs in RCTs are Remdesivir, Favipiravir, and Galidesivir, though Galidesivir RCT is currently recruiting patients (NCT03891420) with no preliminary results available yet [43]. In fact, the most promising drug for the treatment of COVID-19 is Remdesivir. It showed a significant decrease in the viral load despite some safety concerns. In the last preliminary report of the RCT conducted to investigate Remdesivir (NCT04280705), a shorter recovery time of 11 days was observed in patients requiring oxygen who received Remdesivir as compared to the group of patients that received the placebo (15 days recovery time). Adverse events were observed in 21.1% of patients who were randomized to Remdesivir, compared to the placebo group of 27% adverse events [44]. Currently, the Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Remdesivir for the treatment of adult and children COVID-19 patients [45]. From a pharmacological scope, Remdesivir is a prodrug that is metabolized into an alanine metabolite upon entry to the cell (GS-704277) that is afterward processed into a monophosphate derivative and then to the active nucleoside triphosphate derivative. It acts as a competitive inhibitor for the incorporation of native adenosine triphosphate into the growing polynucleotide chain. Moreover, it displays linear pharmacokinetics with a long half-life (>35 for the parent drug) [46]. Another RCT for Favipiravir (ChiCTR2000030254) showed that patients who received the drug had shorter latencies for fever and cough relief than patients who took another repurposed drug (Umifenovir), which will be discussed later in this review. Also, it demonstrated a clinical recovery

rate of 7 days. The only adverse effects observed were a rise in serum uric acid level that is mild and manageable [47]. Another RCT is currently conducted to assess Favipiravir in combination with Nafamostat Mesylate (an anticoagulant discussed later in this review) and to compare this combination with administering Favipiravir alone [48] (Fig. 1).

2.1.2. Protease inhibitors

Some protease inhibitors were assigned for repurposing to treat COVID-19 owing to their potential ability to prevent the maturation of major proteins in the viral life cycle. These drugs are lopinavir/ritonavir combination, Darunavir, TMC-21091, and TMC-210911 [49]. *In silico* studies of drug-enzyme binding have shown potential interactions between 20 protease inhibitors and the main SARS-CoV-2 protease. Accordingly, Other HIV protease inhibitors have been selected as drug candidates using computational methods but did not yet undergo *in vitro* tests or clinical trials.

Even though the lopinavir/ritonavir combination showed an effective inhibition *in vitro*, an RCT (ChiCTR2000029308) aimed to investigate its effect on the late stage of COVID-19 patients with oxygen saturation (SaO₂) of 94% or lower, compared to patients receiving standard care alone, showed no benefit beyond the standard care. Since this RCT was performed on patients with a late stage of pulmonary infection, it might be misguided to conclude that lopinavir/ritonavir has no benefit whatsoever because other severity stages like the first stage of viral replication or immune hyper-reactivity were not assessed against this drug combination [50, 51] (Fig. 2).




Fig. (1). Chemical structures of the nucleoside analogues repurposed for the treatment of SARS-CoV-2.




Fig. (2). Chemical structures of the protease inhibitors used for SARS-CoV-2 treatment.

2.1.3. Neuraminidase Inhibitors

Neuraminidase is an essential enzyme in the influenza viral life cycle. A sequence comparison study found a similarity in the neuraminidases of H1N1, NS1, and NS2 of SARS-CoV-2. Based on this study, neuraminidase inhibitors have been suggested for repurposing to treat COVID-19. However, there are some concerns about the viral resistance for these agents. To date, there is no sufficient evidence for the effectiveness of neuraminidase inhibitors for the treatment of COVID-19. But, CDC has recommended the repurposing of three neuraminidase inhibitors; Oseltamivir, Zanamivir, and intravenous Peramivir [52, 53] (Fig. 3).

2.2. Repurposing of Corticosteroids

Corticosteroids are thought to be among the most important adjuvant therapies for reducing the severity and mortality of COVID-19. The late stage of the disease leads to cytokine storms that consequently cause damage to multiple organs. It has been reported that dexamethasone and methylprednisolone have positive impacts on improving the dysregulated immune responses and regulation of hypotension. In a retrospective cohort study, 201 COVID-19 patients who developed ARDs and were treated with methylprednisolone showed a significant reduction in the mortality rate [54]. Another study showed a strong correlation between the administration of methylprednisolone and both improved

symptoms and reduction in latency in patients who developed acute respiratory failure and showed symptoms like fever and hypoxia, compared to patients who did not receive the drug [55]. In addition, Dexamethasone has shown a reduction in mortality and the ventilation period in ARD patients. More evidence and larger-scale studies are still needed (Fig. 4).

2.3. Antibiotic and Antifungal Agents

Antibiotic agents should only be used in the case of procalcitonin (PCT); as a result of ventilator-associated pneumonia or hospital-acquired pneumonia. Non-RCTs trials showed the effectiveness of Teicoplanin in the treatment of COVID-19 as it potently blocks the entry to the cell [56]. In addition, Azithromycin has been tested but showed cardiac toxicities in the form of prolongation of QT interval [57]. Also, an observational study has shown that doxycycline improves respiratory symptoms and COVID-19 associated anosmia [58] (Fig. 5).

2.4. Anticoagulants

It has been found that there is a variation between reported incidences of Venous Thromboembolism (VTE) in hospitalized COVID-19 patients. VTE therapy should be given to adult hospitalized patients only per the standard care for hospitalized adults.




Fig. (3). Chemical structures of the neuraminidase inhibitors used for SARS-CoV-2.




Fig. (4). Chemical structures of repurposing of corticosteroids used for SARS-CoV-2.





Fig. (5). Chemical structures of antibiotic and antifungal agents used for SARS-CoV-2 treatment.

Data from various clinical trials associate infection of SARS-CoV-2 with a prothrombotic state, with increases in fibrin, fibrinogen, fibrin degradation products, and D-dimers [59, 60]. Therefore, anticoagulant therapy is crucial in treating COVID-19 due to the hypercoagulable state that has been observed in COVID-19 patients that consequently leads to different stages of thrombosis. Low molecular weight heparin therapy has shown a reduction in mortality by prevention or treatment of thrombosis in severe COVID-19 patients [61]. Moreover, Heparin can contribute to the inhibition of viral attachment owing to its potential in causing conformational changes to spike S1 of SARS-CoV-2, in addition to Heparin's anti-inflammatory properties [62]. Another therapeutic approach to inhibit the thrombo-inflammatory response is the inhibition of the contact factor inhibitory pathway targeting coagulation factor XII. Using an FXIIa inhibitory antibody is a

potential therapy in this approach. In fact, it is currently being investigated in a clinical trial (NCT03712228). Also, fibrinolysis therapy has shown promising results using plasminogen activator (tPA), a fibrinolytic agent that converts inactive plasminogen into plasmin which in turn breaks down cross-linked fibrin. In a recent clinical trial, it has been observed that nebulized fibrinolytic therapy correlates with better oxygenation and ventilatory parameters [63]. Recently, agents with antiplatelet effects like dipyridamole and Nafamostat have shown effective results in *in vitro* studies by suppressing SARS-CoV-2 and previously MERS, respectively [64, 65]. Nafamostat is a serine protease inhibitor with antiplatelet effects and is known to inhibit TMPRSS2 [66]. Currently, the RACONA RCT (NCT04352400) is aiming to investigate the efficacy of Nafamostat in severe COVID-19 patients (Fig. 6).



20 Dipyridamole

21 Nafamostat

Fig. (6). shows the chemical structures of anticoagulants used for SARS-CoV-2 treatment.

3. IMMUNE-BASED THERAPY

3.1. Convalescent Plasma and Immunoglobulins

Convalescent Plasma (CP) is the plasma donated from already cured patients that include antibodies against SARS-CoV-2. In addition, concentrated immunoglobulin preparations from the plasma of recovered patients have also been used. The CP therapy has been effective in SARS, MERS, and 2009 H1N1 pandemics [67 - 70]. The high virological and clinical data similarity between these viruses and SARS-CoV-2 strongly promoted trying CP therapy for the treatment of COVID-19. A pilot study was conducted on 10 severe COVID-19 patients with various symptoms. The results were that all symptoms of the 10 patients, including fever, cough, chest pain, shortness of breath, vastly improved from 1 to 3 days. Moreover, chest CT examinations showed a reduction in pulmonary lesions with much better pulmonary function. Also, 5 of the 9 patients achieved an increase in the amount of the neutralized antibody titers. Before the CP transfusion, 3 of the 10 patients were tested negative of the SARS-CoV-2 RNA by qRT-PCR assay, while the other 7 were tested negative after CP transfusion, three of them on day 2, the other three on day 3, and the last one on day 6. No serious adverse effects of CP therapy were observed. The results achieved show the effectiveness of using CP therapy for the treatment of COVID-19 [71].

3.2. Interleukin-1 Inhibitors

One of the signs of COVID-19 is the elevation of endogenous Interleukin-1 (IL-1) along with cytokine release syndrome. Thus, using IL-1 inhibitors is of potential therapeutic value [72]. A recent case report stated that subcutaneous Anakinra (an IL-1 receptor antagonist) treated COVID-19 as a monotherapy. It reports a rapid and continuous improvement of respiratory manifestations and fever. After 10 days, the inflammatory parameters of the patients were improved. On day 19, the patient was discharged with no need for oxygen supplementation, and the chest CT showed improvement of the pulmonary infiltrates [73].

3.3. Interleukin-6 Inhibitors

It has also been found that elevation of IL-6 is a normal response of severe systemic inflammatory response in severe COVID-19 patients [74, 75]. This makes the IL-6 blockade of therapeutic significance. The following IL-6 inhibitors were tested; Sarilumab, Siltuximab, and Tocilizumab. A clinical trial to investigate the effect of Sarilumab (NCT04315298) showed a significant reduction of the C-reactive protein levels and the overall mortality rate. Adverse effects included reversible elevations in liver enzymes, seldom occurrences of neutropenia, and thrombocytopenia. Some risk of serious infections was also reported in the case of long-term usage of Sarilumab. Regarding Tocilizumab, an RCT (NCT04331808) showed that it improved symptoms and had a great effect on reducing the mortality rate. However, detailed results have not been published yet [76].

3.4. Interferons

Interferons alfa/beta are only recommended for clinical studies and not for treatment purposes. An RCT using interferons in combination therapies on 301 patients showed no improved symptoms and had no benefit over the standard care [77]. Therefore, more research should be done to reach a conclusion on their effect.

4. BIOINFORMATICS

Once the data of the SARS-CoV-2 genome were published on The National Center for Biotechnology Information (NCBI) and Global Initiative on Sharing All Influenza Data (GISAID) database, various studies related to bioinformatics analysis had appeared providing significant information for the SARS-CoV-2 treatment. Bioinformatics analysis helps to determine the gene structure, evolution, mechanisms, and function, as well as prediction of possible epitopes. The combination of bioinformatics analysis, epidemiological data, and experimental outputs may give an indication for improving the selection of an animal model for *in vivo* experiments [78].

4.1. Network Bioinformatics Analysis

The gaps in the information of COVID-19 have to be filled up by the quick sharing of relevant data [79]. In the United Kingdom (UK), a network called “COVID-19 Genomics UK (COG-UK) Consortium” was launched to provide sequence data for 230 thousand SARS-CoV-2 samples from different patients [80]. In addition, various bioinformatics networks were established for the investigation of drug repurposing [81, 82]. Another approach is to build a network model for the viral-host interactome using protein-protein interactions for previous HCoV S-glycoprotein to study the pathogenicity of SARS-CoV-2 [83]. The master regulator analysis was conducted to predict most of the human interactome influenced by infection [84]. The network-based on gene interaction and pathway tracking has assisted in obtaining a reference for clinical studies [85]. A group from the University of Alabama developed a network including multi-omics data called “Calu-3-specific human-SARS-CoV-2 Interactome” which comprises information about novel molecular components and pathogenicity [86]. Another group adopted a systems biology approach that accesses precious information about miRNA data and transcriptome, yielding an understanding of the binding and replication machinery for SARS-CoV-2 [87]. The Network bioinformatics analysis has a significant role in finding a treatment for COVID-19 by predicting 24 pathways, 34 genes, 5 modules, and more than 30 drugs that could be potentially repurposed [88,89].

4.2. Evolution and Conservation

The replicative machinery is evolving in SARS-CoV-2 at a high rate, which can produce different mutations along the genome [90]. There was no evidence for intra-host mutation until the end of 2020 [91]. In 2021, this evidence appeared in patients worldwide and should not be neglected [92 - 94]. The genotyping analysis for SARS-CoV-2 was applied using fast multiple sequence alignment followed by directed Jaccard distance as an approach to provide information about the presence of mutations and Single Nucleotide Polymorphisms (SNPs) [95]. The mutation in essential proteins such as RdRp [96], Non-Structural Protein 6 that has a role in viral autophagy [97], and S protein [98] and the deletion [99] should be considered during the development of effective treatments. This is also important for designing a set of primers for the diagnosis of the SARS-CoV-2 using reverse-transcribed quantitative PCR (RT-qPCR) [100]. The conservation domains in other viruses such as poliovirus and bronchitis with SARS-CoV-2 polypeptide-1 can be significant clues for developing a vaccine [101]. On the other hand, the phylogenic tree is a powerful tool to estimate the origin of the virus and predict if the evolution occurred by nature or in the laboratory [102, 103]. Various classifications were made according to the occurrence of SNPs in the genome, such as the S and L lineages, by noticing the orflab T8517C, sense mutation, and ORF8 C251T [104]. By using the single nucleotide variations, Yang *et al.* classified the virus into six phylogenetic clusters with a relation between the mutation and the mortality rate [105]. Another study has used SNPs for classifying the virus into four groups. One of them was proved more aggressive [106]. The trials started to design a barcode of 10 SNPs in the

genome to facilitate the tracking process [107]. In addition to SNPs, the recombination and insertions specifically at the cleavage site of the receptor-binding domain may increase the ability to infect the host cell [108].

4.3. Prediction of Epitopes

Identification of the part of the virus genome that is recognized by immune responses in the human gives a great opportunity for designing a new vaccine and assists in evaluating vaccine candidate immunogenicity. To date, various studies are being conducted to predict T and B cells epitopes using different bioinformatics tools. The strategy of finding conserved parts in the viral genome with newly acquired adaptations can be used to generate hypothetical B cell epitopes [109]. The Immune Epitope Database and Analysis Resource (IEDB) [110] and The Virus Pathogen Resource (ViPR) [111] are two resources for known epitopes. They were used to predict candidate targets for SARS-CoV-2 based on previously known epitopes from other coronaviruses [112]. In addition, the BepiPred 2.0 server has recently been used to identify B-cells epitopes for the virus [113, 114]. The strategy based on 9-mer epitope prediction can provide epitopes through HLA class I alleles [115]. The conservation between SARS-CoV and SARS-CoV-2 in S and N proteins was a significant starting point to produce preliminary data for T cells epitopes [116]. The X-ray crystal structure of the conserved cryptic epitope (CR3022), which is known as a neutralizing antibody for SARS-CoV [117], in complex with the S protein of the SARS-CoV-2 may highlight its role as an essential target [118]. However, around 24.5% of amino acids in S protein are different from SARS-CoV which opens the track to predict unique antibody epitopes that may have a significant effect [119].

5. MOLECULAR MODELLING

In the absence of effective treatments or vaccines against COVID-19, and because of the adverse impact the COVID-19 brought on the work environment worldwide, the role of computational approach and *in silico* studies dramatically emerged. Structural biology, homology modeling, and molecular docking exhibited a fundamental role in the ongoing trials for the discovery of COVID-19 therapy.

5.1. Structural Biology

Elucidation of the 3D structure of SARS-CoV-2 essential subunits has a substantial role in drug discovery, particularly through molecular docking. Therefore, many scientists dedicated their time and effort to resolve the crystal structure of vital proteins in SARS-CoV-2 as well as the binding pockets and the key amino acids. This would pave the way for structure-based drug design for COVID-19 treatment. The determination of the 3D crystal structures of SARS-CoV-2 proteins was performed mainly by X-ray crystallography (XRD) [34, 118, 120 - 130]. Also, Cryogenic Electron Microscopy (Cryo-EM) produced some 3D structures but less than those obtained from XRD [131 - 139]. On the other hand, Nuclear magnetic resonance (NMR) had a minor role in detecting SARS-CoV-2 crystal structures. Till October 2020, there was only one protein structure of this virus obtained using

NMR, representing the nucleocapsid protein (N) (PDB ID: 6YI3). However, during the first half of 2021, the number of structures was increased by 3, which can be found in the protein data bank as solved structures using solution NMR under the Source Organism Taxonomy Name = “SARS-CoV-2” in the search bar. The 3D structures have been elucidated for many protein types in SARS-CoV-2, either structural or Nsps Table (S2). One of the most important structural proteins detected in the 3D form is the S protein obtained by Cryo-EM [132 - 134]. Additionally, another study elucidated the S protein by Cryo-EM in a closed state (PDB: 6VXX) and an open state (PDB: 6VYB) [135]. Another resolved structural protein of SARS-CoV-2 is the N protein, obtained using XRD (6WZO, 6WZQ, and 6M3M) and NMR (PDB: 6YI3) [121, 122]. On the other hand, the Nsps detected include RdRp, which was obtained by Cryo-EM [137, 138].

Since the main protease (M^{pro}), also known as 3C-like Main Protease ($3CL^{pro}$), is a versatile drug target, many crystal structures were prepared and submitted to the PDB, and many of them are still from unpublished data [123 - 126]. The most commonly used M^{pro} crystal in the process of structure-based design is 6LU7 [123]. Several crystal structures were also published for papain-like protease (PL^{pro}) and NSP15 [127, 128]. It is worth noting that some viral protein structures were determined as a portion of a complex, such as NSP12-NSP7-NSP8 obtained by Cryo-EM [139]. The elucidated proteins are crystallized, in varying qualities, either alone in an unbound state or complex with a ligand (Table S1, updated until 31 of March 2021 Supplementary Data). The role of structural biology can be significant in predicting the architecture of the SARS-CoV-2 proteome [140].

The Protein data bank returns 1232 structures after using Source Organism Taxonomy Name = “SARS-CoV-2” as a keyword for search, updated 26 May 2021. The data was distributed among X-ray diffraction, Electron microscopy, Solution NMR, Solid-state NMR, and Neutron diffraction, and the numbers of structures were 898, 330, 3, 2, and 1, respectively. It was obvious that X-ray is the most abundant tool worldwide due to the high resolution of the structures with refinement resolution $<2 \text{ \AA}$ that is only found among x-ray structures. Those data come up with this unusual speed as a result of extensive partnership and collaboration around the world in a search to find a solution to stop the SARS-CoV-2 breakout [79]. However, unfortunately, the more quickly work is done, the more errors and incorrect information appear. Several structures were studied and submitted in non-peer-reviewed journals that build a large library of misleading information, and this issue was discussed in detail with requests to enhance SARS-CoV-2 structures elsewhere [141].

The computational works in structural biology can be extended to include predicting the 3D structures by using various tools, including AlphaFold as an *Ab initio* tool based on deep neural networks [142] that have been used in predicting ORF8 [143], NSP6 [144], or other SARS-CoV-2 proteins [145]. Although this technique is promising in the case of building novel proteins, the high computational cost makes homology modeling crucial.

5.2. Homology Modeling

Due to the rapid mutation in the SARS-CoV-2 and since the process of crystallization consumes time and effort and is not feasible in certain cases, many scientists exploited computational approaches to predict the structure of specific proteins in SARS-CoV-2 through homology modeling. This is done by first retrieving the sequence of the virus target protein and aligning this sequence with the experimentally solved proteins with the best homology. Since there is high conservation between SARS-CoV-2 and SARS-CoV, around 80% nucleotide sequence identity [146], the SARS-CoV 3D proteins are usually used as templates to perform the protein modeling. Once the sequence alignment is available, homology modeling software uses a specific algorithm to fold the target protein using structural information obtained from the template.

A recent study attempted to predict the 3D structure of SARS-CoV-2 E protein from its sequence in NCBI, accession number YP_009724392, using the ITASSER server and exploiting the corresponding protein from SARS-CoV (PDB ID 5X29) as a template [147]. This protein was used as a template due to the conservation with the SARS-CoV-2 E protein with 88.71% sequence identity [147]. Regarding the M protein of SARS-CoV-2, a study generated its 3D model, based on SARS-CoV M protein, using its sequence from NCBI, Accession number QHD43419, and the ITASSER server [147]. Similarly, the S protein 3D model was developed using SARS-CoV S protein as a template and Modeller software [148 - 150]. Also, the 3D model of the RdRp protein structure has been built using the SWISS-MODEL server and the corresponding SARS-CoV protein as a template [149, 151, 152]. The 3D models for some SARS-CoV-2 proteases such as PL^{pro} and M^{pro} were also developed using the SWISS-MODEL server and Modeller software [149, 152]. Finally, the 3D structure of Guanine-N7 methyltransferase, known as nonstructural protein 14 (nsp14), was predicted by using Modeller software based on SARS-CoV nsp14-nsp10 complex (PDB ID 5C8S) [153].

The spike and Orf8 for the new variant SARS-CoV-2/B.1.1.7 were predicted by the Swiss model for antibody binding site prediction [154]. In this study, the template was solved using Cryo-EM that has a lower resolution compared to other experimental tools [155]. ACE2 protein sequence homology was used to estimate the risk of SARS-CoV-2 infection in animals. However, the authors did not support this hypothesis with reported cases [156]. Overall, the results coming from predictions based on another prediction are not preferred in science as the percentage of error becomes high.

5.3. Molecular Docking and Virtual Screening

The process of drug discovery consumes significant time and resources until it reaches the clinical trial stages before introducing approved drugs to the market. Therefore, molecular docking has been employed to suggest potential lead compounds that are likely to target SARS-CoV-2 specific proteins or host cell proteins essential for viral entry and survival. These candidates are not guaranteed to have an actual efficacy toward the targets until *in vitro* and *in vivo* validations

are available.

Several studies performed docking using FDA-approved drugs with known efficacy and toxicity [149, 151, 157 - 160]. Other studies investigated the interaction of natural products or extracts with various SARS-CoV-2 proteins [147, 161 - 166]. Moreover, scientists exploited several libraries of commercially available drug-like compounds for docking into the viral proteins. The most prominent databases used are PubChem [162, 163], ZINC database [149, 152, 160], ChemSpider [157, 165], Drug Bank database [158], TIPdb database [166], Indian Medicinal Plants, and Phytochemistry and Therapeutics (IMPPAT) database [147]. The most commonly used docking programs to detect the binding affinity between the protein target and the compounds are AutoDock Vina [147, 151, 152, 161, 165], GOLD suite [161], Schrodinger glide docking module [148, 159, 162, 167], Swiss Dock [157], AutoDock [158, 166], and idock [164]. The aforementioned programs utilize algorithms to sample the conformational space of the protein-ligand complexes to identify the accurate binding mode, followed by calculating the affinity score of the complex to determine the low energy configurations as the accurate binding mode [168, 169]. However, they act differently about the algorithms used, the scoring function, and the protein-ligand representation [168, 170].

The target structure is either retrieved from Protein Data Bank (PDB) or predicted by homology modeling. There are a large number of molecular docking studies targeting SARS-CoV-2 structural proteins such as S protein [148, 149, 162, 165], envelope protein (E) [147, 166], membrane protein (M) [147], and N protein specifically the N-terminal domain (NTD) [167]. As mentioned above, spike (S) protein is the main tool used by the virus for entry into the host cell. Therefore, several studies aimed at predicting the interaction of this protein with host receptors as well as with small candidate ligands [162, 162]. The databases used for docking include the well-known ZINC database of commercially available compounds, a library of natural products, and in-house libraries of the developing companies. Additionally, Nsps such as PL^{pro} or Nsp3 [149, 158], M^{pro}, and Nsp5 were also used for virtual screening [148, 149, 152, 157, 159 - 161, 163]. The viral main protease (M^{pro}) is a cysteine protease responsible for cleaving the large polyprotein at more than ten sites, usually at the amino acid sequence Leu-Gln-(Ser, Ala, Gly). This protein acts as a dimer with a limited catalytic activity of the monomers. To date, no M^{pro} inhibitors have been approved by the FDA for treatment of COVID-19, and only Pfizer reported a ligand, PF-07304814, with activity on this enzyme. There are a large number of reported crystal structures of this viral protein and a surprising number of *in silico* studies describing the discovery of inhibitors for the treatment of COVID-19 [124-127, 157-163]. Most of the recent studies focus on the screening of FDA-approved compounds. However, we noticed that in most cases and despite the conclusive titles, these studies are merely theoretical and are not validated by biological evaluation. We believe that, under this pandemic situation and with the increasingly available and more affordable assay formats, all these virtual screening campaigns should be concluded with an *in vitro* protease assay.

Notably, Papain-like protease (PL^{pro}) is also considered an important drug target because of its substantial role in polyproteins cleavage. The PL^{pro} catalyzes the proteolytic cleavage at nsp1/2, nsp2/3, and nsp3/4. It is a cysteine protease that has the conserved catalytic triad Cys111-His272-Asp286, which targets the P1-P4 sequence GGXL [127]. The PL^{pro} is the least explored target among the characterized molecular targets of the SARS-CoV-2, relative to the 3CL^{pro} on which extensive studies have been made, the RdRp, which is the target of the only FDA-approved drug for Covid-19 treatment, and the S protein used in vaccine development. In a previous "all-theoretical" study, the authors suggested repurposing some FDA-approved drugs as PL^{pro} inhibitors, however, without offering any biological evaluation or even molecular dynamics (MD) explanation. Other studies proposed novel potential inhibitors of the PL^{pro} but the lack of cellular antiviral confirmation is considered a substantial limiting step in most of these studies [171].

Furthermore, molecular docking was also performed into viral Nsp15 endoribonuclease (NendoU) [162], RdRp, Nsp12 [149, 151, 152, 164], and helicase (Nsp13) [149, 152]. On the other hand, a host cell protein structure could be a drug target to inhibit the SARS-CoV-2 infection. These host cell targets include Angiotensin-Converting Enzyme 2 (ACE2) receptor, which binds to the viral S protein during cell entry [149, 165], and TMPRSS2, which is a protease essential in S protein cleavage and facilitates viral entry [149].

Currently, molecular docking studies are validated by molecular dynamics simulations for further understanding of the binding interactions. It is nearly the gold standard procedure in SARS-CoV-2 molecular dynamics drug repurposing research. For example, Muralidharan and colleagues used AutoDock to search for potential inhibitors for M^{pro}. In addition, they simulated each one of the obtained three proteins and all of them together. The molecular dynamics simulations revealed the raising binding potential of lopinavir, oseltamivir, and ritonavir with the M^{pro} from -5.11 to -8.32 kcal/mol [172]. Generally speaking, molecular docking methods are a broadly active area of research, particularly with the lack of resources and time in the era of the pandemic (Fig. 7). For example, high throughput screening to obtain the best hits was done based on 1.3 billion compounds that were docked against M^{pro} using a novel technique called "Deep docking" [173]. Also, the interaction between nanoparticles and different proteins was identified using molecular docking [174]. However, there is insufficient data regarding using the docking tool to predict the interaction between nanoparticles and SARS-Cov-2, especially after confirming the antiviral role of nanoparticles [175, 176]. The process of docking was extended to include the peptide-protein interaction between nisin, a peptide that works as an antimicrobial in food preservation, and human ACE2 [177, 178]. This work opens the track to use our food as a significant tool in curing the disease. A recent study predicted the protein-protein interaction between neural proteins such as A β , α -synuclein, tau, prion, and TDP-43 RRM and SARS-CoV-2 Spike S1 protein receptor using docking [179]. This work illustrates the importance of docking in explaining the reasons behind the high risk of

catching a neurodegenerative disease for people infected with SARS-CoV-2 [180]. Due to the significant role of docking studies, several databases specific for SARS-CoV-2 docking results should be built and made available to the public in order to accelerate the COVID-19 emergency drug discovery. For example, various ligand-protein and protein-protein interactions could be easily accessed throughout the user-friendly free-to-access SARS-CoV-2 3D database at <https://sars3d.com/> [181].

5.4. Pharmacophores and QSAR Models

Ligand-based drug design approaches depend on using information gained from molecules active on the target of interest to provide guidance for the design of novel ligands. Typically, several ligands with high affinity to the protein target are required, while the 3D structure of the target is not necessarily solved. Since the outbreak of COVID-19, many research groups have developed both ligand- and structure-based pharmacophores as well as QSAR models to describe the binding determinants of the biological targets that could be targeted for the treatment of this disease. We will provide examples of the models developed for each biological target. However, this is not meant to be an exhaustive list. As mentioned above, the SARS-CoV-2 main protease (M^{pro}) draws great attention with several pharmacophore models reported. Recently, Saeed *et al.* have developed a receptor-based pharmacophore model for the M^{pro} for identifying FDA-

approved drugs and hits from natural products [182]. This model was based on the M^{pro} crystal structure (PDB ID: 6LU7) and consisted of a hydrogen bond acceptor, donor, and hydrophobic features. Similarly, scientists from UC San Diego have reported a structure-based pharmacophore of the SARS-CoV-2 RDRp based on its crystal structure with Remdesivir (PDB ID: 7BV2) [182]. This “huge” model consists of two acceptors, three donors, one acceptor and donor, three donors or acceptor, one hydrophobic, and an excluded volume of $R=1.1 \text{ \AA}$. In another study published in May 2021, a Korean team developed a structure-based pharmacophore for the S-adenosyl methionine binding site of the nsp10-nsp16 complex based on its crystal structure (PDB ID: 6W4H) [183]. Their best model was composed of 2 hydrogen bond acceptors, 2 hydrogen bond donors, and 2 positive ionizable to screen the DrugBank database resulting in three hits. On the other hand, a ligand-based pharmacophore was also developed for the host protein Transmembrane serine protease 2 (TMPRSS2), based on four serine protease inhibitors (camostat mesylate, nafamostat, pefabloc SC, and phenylmethylsulfonyl fluoride) and two Janus-associated kinase inhibitors (baricitinib and ruxolitinib). The selection of these compounds was based on previous reports of promising anti-COVID-19 activity. However, the authors did not provide convincing evidence of the relationship of these agents to the TMPRSS2. This model was then used for screening the ZINC database for commercially available hits [184].




Fig. (7). Various programs and databases used in virtual screening and molecular docking for SARS-CoV-2.

It is worth noting that the majority of these studies prioritized certain hits based on virtual screening, docking, and/or molecular dynamics simulation without performing *in vitro* biological evaluation against the studied protein targets. We perceive this as a serious limitation that undermines the results of these studies, and we suggest that future studies should be complemented by enzyme assays. These assays are getting more affordable over time due to the increasing interest of the scientific community in studying SARS-CoV-2 biology. Furthermore, most of the reported pharmacophores, especially those of viral proteins, are based on crystal structures (structure-based) rather than a collection of active ligands. Structure-based pharmacophores usually possess too many chemical features making them too restrictive and sub-optimal for virtual screening purposes. Moreover, these models cannot reflect the quantitative structure-activity relationship (QSAR) and, hence, cannot be used for activity prediction because they are derived from a single macromolecule–ligand complex.

Similarly, several QSAR models were developed to describe the electronic and steric features of the ligands of various proteins targeted for COVID-19 treatment. For example, Tejera and co-workers used a machine learning strategy to generate a QSAR model based on hundreds of inhibitor molecules of the main protease (M^{Pro}) of the SARS-CoV coronavirus (the virus responsible for the 2003 outbreak) [185]. These compounds were selected due to the limited number of ligands reported for the new SARS-CoV-2 and, also, the significant similarity between the structure and sequence of SARS-CoV and SARS-CoV-2 M^{Pro} proteases. The authors used the ChEMBL database to retrieve all the compounds reported to interact with the SARS-CoV M^{Pro} . Then, they used a subset of all the ligands with an IC_{50} of less than 10 μ M. This model was subsequently used for screening DrugBank, and the hits were then docked into the SARS-CoV-2 M^{Pro} . Finally, the authors suggested twenty hits for further study. In another interesting study, scientists from the University of North Carolina developed QSAR models based on 113 compounds with known activities against SARS-CoV M^{Pro} . Similarly, the research team collected all the ligands with reported activity on the SARS-CoV M^{Pro} in the ChEMBL database and used a threshold of 10 μ M to differentiate them into actives (40) and inactives (73). The authors employed several QSAR techniques, including SiRMS, which uses fragment-based descriptors including several physical-chemical parameters, such as atoms' lipophilicity and partial charges, and Dragon, which adopts whole-molecule descriptors; constitutional, topological, and geometric. These models were used to screen 9,615 compounds in the DrugBank database and yielded 42 Hits. Subsequently, the National Center for Advancing Translational Sciences (NCATS) tested 11 of these 42 hits, and three of them, cenicriviroc, proglumetacin, and sufogolix showed micromolar activities against the SARS-CoV-2 M^{Pro} [186]. There is no doubt that the M^{Pro} is an important and promising target for fighting COVID-19. We believe that depending on the SARS-CoV M^{Pro} ligands for the design of inhibitors of the SARS-CoV-2 enzyme was justified during the early days of drug discovery for this pandemic. However, with the increasing number of agents acting on the SARS-CoV-2 main protease, we think that future QSAR

studies should depend merely on SARS-CoV-2 ligands. In addition to the M^{Pro} QSAR models, Amin *et al.* used 91 known inhibitors of the SARS-CoV PL Pro to create a total of 21 models based on SMILES and graph-based descriptors. The best model was then used to screen an in-house library of small molecules and the top hits were docked into the crystal structure of the SARS-CoV-2 PL Pro . This approach resulted in prioritizing thirteen compounds for further biological evaluation [187]. Interestingly, scientists from Lanzhou University, China, developed a QSAR model for 27 natural products based on their non-specific antiviral activity against SARS-CoV-2 without information about binding to certain biological targets. This model was based on two descriptors; Final Heat of Formation/number of Atoms (FHFA) and Max Antibonding Contribution of a Molecular Orbital (MACMO), and showed a correlation coefficient of 0.91 [188].

Despite the significant number of the QSAR models describing the activity of a large number of compounds towards various SARS-CoV-2 targets, none of these models was actually used for actual drug discovery campaigns complemented by biological evaluation. Again, these studies aimed at recommending certain hits for further future studies. In addition, due to the relatively low number of reported compounds with *in vitro* activities towards SARS-CoV-2, a lot of these QSAR models were based on activity data on the SARS-CoV of 2003 outbreak and tried to extrapolate their conclusions to the SARS-CoV-2. This also represents a serious limitation, and we recommend building future QSAR models using biological data from SARS-CoV-2 assays only because these data became more available and usually freely accessible.

5.5. The Advantage and Disadvantage of *In Silico* Drug Discovery

Recently, *in silico* strategies in drug repurposing and drug discovery have been widely used due to the high cost and the time required to identify therapeutic molecules in the laboratory [189]. Computational methods aim to identify a small set of molecules with therapeutic function against the targeted protein based on the protein-ligand interactions. Moreover, computational methods enable the integration of toxicity, metabolism, and adsorption profiling to eliminate off-target molecules. It also enables identifying a single molecule against different protein targets [190]. On the other hand, some of the common pitfalls of the computational methods are the false-positive results and the essential need for combined ligand- and structure-based methods or further *in vitro* assays [191]. In this regard, computational methods can be divided into data modeling approaches and virtual screening. Data modeling approaches statistically determine the relationship between the structural properties and the pharmacodynamics and pharmacokinetics properties, described as Quantitative Structure-Activity Relationships (QSAR), in order to make predictions. Regarding virtual screening for SARS-CoV-2 drug discovery, protein-ligand docking is still the most structure-based method, which specifies the ligand-binding site and evaluates its affinity [192]. The virtual ligand screening approach enables the filtration process of the different libraries to identify target-specific molecules based on the predicted affinity to this biological target [192].

The *in silico* computational approach has made an obvious contribution to antiviral repurposing over the last decades. Interestingly, different workflows were used to develop a therapeutic drug against SARS-CoV [193]. For example, Nguyen *et al.* revealed the promising 3CL^{Pro} inhibitors by virtual screening of over 300 thousand molecules and obtained 53 compounds to be tested *in vitro*. The study resulted in the identification of two potential 3CL^{Pro} inhibitors [194]. Similar computational studies were conducted recently during the SARS-CoV-2 pandemic. For instance, Sepay and his colleagues tested the chromanone's derivatives, showing an inhibitory effect against the M^{Pro} of SARS-CoV-2 [195].

5.6. The Pros and Cons of Wet Laboratory Research in Pandemic Era

In vitro studies enable the characterization of the viral life cycle, evolution, and infectivity. The main advantage of *in vitro* studies is the preliminary drug investigation and assessing the safety, toxicity, pharmacokinetics, and metabolism without exposing animal or human subjects to the risk of the experimental drugs [196]. However, most of the *in vitro* proved functional molecules failed in phase I clinical trials. For instance, numerous studies revealed the potential effect of remdesivir against SARS-CoV-2 when applied on Vero E6 cells *in vitro* [197, 198]. Conversely, different clinical studies have shown the limitations of using remdesivir since undesired side effects were observed, like the hepatic enzymes level elevation, rash, elevated bilirubin level, renal impairment, and hypotension. Also, acute kidney injury and multiple organ dysfunction were reported for some participants. In addition, other trials were not continued due to the adverse side effects in reference to the control groups [199, 200].

The third type of current study is *in vivo* experiments on animal models and in clinical trials. Several drugs were repurposed to act against SARS-CoV-2, such as remdesivir, favipiravir, ivermectin, lopinavir, and hydroxychloroquine, and were examined in clinical trials [201]. In other words, clinical trials were designed for the drug repurposing of FDA-approved antimalarials, HIV inhibitors, and other drugs. In contrast, most of the ongoing animal studies are done to investigate newly discovered drugs or vaccines. To illustrate, ChAdOx1 nCoV-19 is an adenovirus-vectored vaccine that encodes the S protein to stimulate the immune response. This vaccine cannot be applied in clinical trials before being investigated for the immunogenic reaction in rhesus macaques as a suitable animal model [202]. Animal models are commonly used during the pandemic as a pre-step in vaccine and drug development [203]. However, many challenges and pitfalls face researchers during conducting *in vivo* experiments due to the ethical considerations during the pandemic situation [204]. On the other hand, the ongoing challenges associated with clinical trials include the limited resources, patient selection, dose identification, the evolution of the viral genome, and the presence of different clades or quasispecies of virus in different populations that may affect the response to repurposed drugs or cause drug resistance [205]. For example, some factors should be considered like age, cardiovascular diseases, diabetes, and gene expression alterations. These factors should be determined in the first place since they are associated with a

higher mortality rate. Therefore, the right drug and dosage need to be carefully selected for different groups of participants [205]. To sum up, the stated pros and cons of the main ongoing types of studies support the notion that *in silico* drug prediction and repurposing is the lowest risk with less off-target results. However, it still requires further investigation *in vitro* or in animal models prior to the clinical investigations.

CONCLUSION

Current treatment strategies depend on drug repurposing with careful evaluation of their efficacy in reducing viral load and relieving disease symptoms with an acceptable safety profile. Also, there are other clinical trials exploring different types of vaccines at different stages of clinical trials. In addition, bioinformatics has an important role in determining the structure, function, and origin of the virus. It could predict possible epitopes for vaccine development and help to choose the optimal animal models for *in vivo* experiments. Different bioinformatics networks also help determine potential drugs for repurposing based on their interaction with different viral structural units. Homology modeling has widely contributed to the prediction of the structure of some viral proteins by retrieving and aligning the sequence and comparing it with the best result of experimentally detected proteins in PDB. Also, molecular docking plays a pivotal role in the prediction of potential compounds that are likely to target SARS-CoV-2 specific structures or host cell proteins essential for viral entry and survival, guiding the design of *in vitro* and *in vivo* studies. Among different types of studies, *in-silico* drug design has lower risk and provides different viable information about safety and efficacy. However, it always requires further validation *in vitro* and *in vivo* on animals and humans.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

The authors thank Fareed Aboul-ela for the critical evaluation of the manuscript's English language.

SUPPLEMENTARY MATERIAL

Supplementary material is available on the publisher's website along with the published article.

REFERENCES

- [1] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *J Med Virol* 2020; 92(4): 401-2. [<http://dx.doi.org/10.1002/jmv.25678>] [PMID: 31950516]
- [2] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. *J Virol* 2020; 94(7):

- e00127-20.
[http://dx.doi.org/10.1128/JVI.00127-20] [PMID: 31996437]
- [3] AA De Vries, MC Horzinek, PJ Rottier, RJ De Groot. The genome organization of the Nidovirales: Similarities and differences between arteri-, toro-, and coronaviruses. In: *Seminars in virology*. Academic Press 1997; pp. 33-47.
- [4] Wu A, Peng Y, Huang B, *et al*. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. *Cell Host Microbe* 2020; 27(3): 325-8.
[http://dx.doi.org/10.1016/j.chom.2020.02.001] [PMID: 32035028]
- [5] Su S, Wong G, Shi W, *et al*. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. *Trends Microbiol* 2016; 24(6): 490-502.
[http://dx.doi.org/10.1016/j.tim.2016.03.003] [PMID: 27012512]
- [6] Zhou P, Yang XL, Wang XG, *et al*. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
- [7] Lau S-Y, Wang P, Mok BW-Y, *et al*. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. *Emerg Microbes Infect* 2020; 9(1): 837-42.
[http://dx.doi.org/10.1080/22221751.2020.1756700] [PMID: 32301390]
- [8] Bosch BJ, Martina BEE, Van Der Zee R, *et al*. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. *Proc Natl Acad Sci USA* 2004; 101(22): 8455-60.
[http://dx.doi.org/10.1073/pnas.0400576101] [PMID: 15150417]
- [9] Xia S, Liu M, Wang C, *et al*. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res* 2020; 30(4): 343-55.
[http://dx.doi.org/10.1038/s41422-020-0305-x] [PMID: 32231345]
- [10] Cyranoski D. Did pangolins spread the China coronavirus to people? *Nature* 2020.
[http://dx.doi.org/10.1038/d41586-020-00364-2]
- [11] Xiao K, Zhai J, Feng Y, *et al*. Isolation and Characterization of 2019-nCoV-like Coronavirus from Malaysian Pangolins. *bioRxiv* 2020.
- [12] World Health Organization. Mission China Joint Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). In: *WHO-China Jt Mission Coronavirus Dis. 2020; 2019*: pp. 16-24.
- [13] Chen Y, Chen L, Deng Q, *et al*. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. *J Med Virol* 2020; 92(7): 833-40.
[http://dx.doi.org/10.1002/jmv.25825] [PMID: 32243607]
- [14] Li Q, Guan X, Wu P, *et al*. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
- [15] Guan WJ, Ni ZY, Hu Y, *et al*. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
- [16] Wang D, Hu B, Hu C, *et al*. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
- [17] Du Y, Tu L, Zhu P, *et al*. Clinical features of 85 fatal cases of COVID-19 from Wuhan a retrospective observational study. *Am J Respir Crit Care Med* 2020; 201: 1372-9.
[http://dx.doi.org/10.1164/rccm.202003-0543OC] [PMID: 32242738]
- [18] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention. *JAMA* 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
- [19] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020; 46(5): 846-8.
[http://dx.doi.org/10.1007/s00134-020-05991-x] [PMID: 32125452]
- [20] Pei G, Zhang Z, Peng J, *et al*. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. *J Am Soc Nephrol* 2020; 31(6): 1157-65.
[http://dx.doi.org/10.1681/ASN.2020030276] [PMID: 32345702]
- [21] Huang C, Wang Y, Li X, *et al*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
- [22] Li X, Wang L, Yan S, *et al*. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. *Int J Infect Dis* 2020; 94: 128-32.
[http://dx.doi.org/10.1016/j.ijid.2020.03.053] [PMID: 32251805]
- [23] Chen N, Zhou M, Dong X, *et al*. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet* 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
- [24] Chan JF, Yuan S, Kok KH, *et al*. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. *Lancet* 2020; 395(10223): 514-23.
[http://dx.doi.org/10.1016/S0140-6736(20)30154-9] [PMID: 31986261]
- [25] Zhang JJ, Dong X, Cao YY, *et al*. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020; 75(7): 1730-41.
[http://dx.doi.org/10.1111/all.14238] [PMID: 32077115]
- [26] Yang X, Yu Y, Xu J, *et al*. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. *Lancet Respir Med* 2020; 8(5): 475-81.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
- [27] Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. *J Med Virol* 2020; 92(4): 441-7.
[http://dx.doi.org/10.1002/jmv.25689] [PMID: 31994742]
- [28] Guo W, Li M, Dong Y, *et al*. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab. Res* 2020; pp. 1-9.
[http://dx.doi.org/10.1002/dmrr.3319]
- [29] Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan. *Crit Care* 2020; 24(1): 108.
[http://dx.doi.org/10.1186/s13054-020-2833-7] [PMID: 32188484]
- [30] Liang W, Guan W, Chen R, *et al*. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. *Lancet Oncol* 2020; 21(3): 335-7.
[http://dx.doi.org/10.1016/S1470-2045(20)30096-6] [PMID: 32066541]
- [31] Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. *Brain Behav Immun* 2020; 87: 184-7.
[http://dx.doi.org/10.1016/j.bbi.2020.05.059] [PMID: 32454138]
- [32] Liu Y, Yan L-M. Viral dynamics in mild and severe cases of COVID-19. *Lancet* 2020; 20: 656-7.
[http://dx.doi.org/10.1016/S1473-3099(20)30232-2]
- [33] Pushpakom S, Iorio F, Eyers PA, *et al*. Drug repurposing: Progress, challenges and recommendations. *Nat Rev Drug Discov* 2018. [PMID: 30310233]
- [34] Shang J, Ye G, Shi K, *et al*. Structural basis of receptor recognition by SARS-CoV-2. *Nature* 2020; 581(7807): 221-4.
[http://dx.doi.org/10.1038/s41586-020-2179-y] [PMID: 32225175]
- [35] Menzella F, Biava M, Barbieri C, Livri F, Facciolo N. Pharmacological treatment of COVID-19: Lights and shadows. *Drugs Context* 2020; 9: 2020-4-6.
[http://dx.doi.org/10.7573/dic.2020-4-6] [PMID: 32499832]
- [36] Ko WC, Rolain JM, Lee NY, *et al*. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. *Int J Antimicrob Agents* 2020; 55(4): 105933.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105933] [PMID: 32147516]
- [37] Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. *Clin Pharmacol Ther* 2020; 108(2): 242-7.
[http://dx.doi.org/10.1002/cpt.1844] [PMID: 32246834]
- [38] Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nat Rev Drug Discov* 2020; 19(3): 149-50.
[http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID: 32127666]
- [39] Khalil JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. *J Med Virol* 2020; 92(7): 740-6.
[http://dx.doi.org/10.1002/jmv.25798] [PMID: 32227493]
- [40] Shahab S, Shekhi M. Triazavirin - Potential inhibitor for 2019-nCoV

- Coronavirus M protease: A DFT study. *Curr Mol Med* 2021. [http://dx.doi.org/10.2174/1566524020666200521075848] [PMID: 32436829]
- [41] Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. *One Heal* 2020. [http://dx.doi.org/10.1016/j.onehlt.2020.100128]
- [42] Sheahan TP, Sims AC, Zhou S, *et al.* An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Sci Transl Med* 2020; 12(541): eabb5883. [http://dx.doi.org/10.1126/scitranslmed.abb5883] [PMID: 32253226]
- [43] A study to evaluate the safety, pharmacokinetics and antiviral effects of galidesivir in yellow fever. *Case Med Res* 2019. [http://dx.doi.org/10.31525/ct1-nct03891420]
- [44] Beigel JH, Tomashek KM, Dodd LE, *et al.* Remdesivir for the treatment of Covid-19 - preliminary report. reply. *N Engl J Med* 2020; 383(10): 994. [http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32649078]
- [45] Eastman RT, Roth JS, Brimacombe KR, *et al.* Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS Cent Sci* 2020; 6(5): 672-83. [http://dx.doi.org/10.1021/acscentsci.0c00489] [PMID: 32483554]
- [46] Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: From Ebola to COVID-19. *Drugs Context* 2020; 9: 2020-4-14. [http://dx.doi.org/10.7573/dic.2020-4-14] [PMID: 32547625]
- [47] Chen C, Huang J, Cheng Z, *et al.* Favipiravir versus arbidol for COVID-19: A randomized clinical trial. *medRxiv* 2020. [http://dx.doi.org/10.1101/2020.03.17.20037432]
- [48] Cai Q, Yang M, Liu D, *et al.* Experimental treatment with favipiravir for COVID-19: An open-label control study. *Engineering (Beijing)* 2020; 6(10): 1192-8. [http://dx.doi.org/10.1016/j.eng.2020.03.007] [PMID: 32346491]
- [49] Harrison C. Coronavirus puts drug repurposing on the fast track. *Nat Biotechnol* 2020; 38(4): 379-81. [http://dx.doi.org/10.1038/d41587-020-00003-1] [PMID: 32205870]
- [50] Cao B, Wang Y, Wen D, *et al.* A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. *N Engl J Med* 2020; 382(19): 1787-99. [http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
- [51] Corrao S, Natoli G, Cacopardo B. A Trial of Lopinavir-Ritonavir in Covid-19. *N Engl J Med* 2020; 382(21): e68. [http://dx.doi.org/10.1056/NEJMc2008043] [PMID: 32369284]
- [52] Tan ELC, Ooi EE, Lin CY, *et al.* Inhibition of SARS coronavirus infection *in vitro* with clinically approved antiviral drugs. *Emerg Infect Dis* 2004; 10(4): 581-6. [http://dx.doi.org/10.3201/eid1004.030458] [PMID: 15200845]
- [53] Monto AS, McKimm-Breschkin JL, Macken C, *et al.* Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. *Antimicrob Agents Chemother* 2006; 50(7): 2395-402. [http://dx.doi.org/10.1128/AAC.01339-05] [PMID: 16801417]
- [54] Wu C, Chen X, Cai Y, *et al.* Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020; 180(7): 934-43. [http://dx.doi.org/10.1001/jamainternmed.2020.0994] [PMID: 32167524]
- [55] Wang Y, Jiang W, He Q, *et al.* Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. *medRxiv* 2020. [http://dx.doi.org/10.1101/2020.03.06.20032342]
- [56] Zhang J, Ma X, Yu F, *et al.* Teicoplanin potently blocks the cell entry of 2019-nCoV. *bioRxiv* 2020. [http://dx.doi.org/10.1101/2020.02.05.935387]
- [57] Gautret P, Lagier J-C, Parola P, *et al.* Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* 2020; 56(1): 105949. [http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
- [58] Bonzano C, Borroni D, Lancia A, Bonzano E. Doxycycline: From ocular rosacea to covid-19 anosmia. New insight into the coronavirus outbreak. *Front Med (Lausanne)* 2020; 7: 200. [http://dx.doi.org/10.3389/fmed.2020.00200] [PMID: 32574320]
- [59] Han H, Yang L, Liu R, *et al.* Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med* 2020; 58(7): 1116-20. [http://dx.doi.org/10.1515/ccclm-2020-0188] [PMID: 32172226]
- [60] Driggin E, Madhavan MV, Bikdeli B, *et al.* Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. *J Am Coll Cardiol* 2020; 75(18): 2352-71. [http://dx.doi.org/10.1016/j.jacc.2020.03.031] [PMID: 32201335]
- [61] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* 2020; 18(5): 1094-9. [http://dx.doi.org/10.1111/jth.14817] [PMID: 32220112]
- [62] Mycroft-West CJ, Su D, Elli S, *et al.* The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. *bioRxiv* 2020. [http://dx.doi.org/10.1101/2020.02.29.971093]
- [63] Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19. *J Thromb Haemost* 2020; 18(6): 1521-2. [http://dx.doi.org/10.1111/jth.14858] [PMID: 32302456]
- [64] Liu X, Li Z, Liu S, *et al.* Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. *Acta Pharm Sin B* 2020; 10(7): 1205-15. [http://dx.doi.org/10.1016/j.apsb.2020.04.008] [PMID: 32318327]
- [65] Yamamoto M, Matsuyama S, Li X, *et al.* Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. *Antimicrob Agents Chemother* 2016; 60(11): 6532-9. [http://dx.doi.org/10.1128/AAC.01043-16] [PMID: 27550352]
- [66] Iwaki MM, Ino Y, Motoyoshi A, *et al.* Effects Studies on the of FUT-175, Enzymes Nafamostat and Mesilate Pancreatic Experimental Acute Pancreatitis in Rats using TAME as an ester-type synthetic substrate, the activated enzyme preparation and 50 mM Tris-HCl buffer (pH 7. Jpn J Pharmacol 1986; 41: 155-62. [http://dx.doi.org/10.1254/jjp.41.155] [PMID: 2427760]
- [67] Cheng Y, Wong R, Soo YOY, *et al.* Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis* 2005; 24(1): 44-6. [http://dx.doi.org/10.1007/s10096-004-1271-9] [PMID: 15616839]
- [68] Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. *N Engl J Med* 2007; 357(14): 1450-1. [9]. [http://dx.doi.org/10.1056/NEJMc070359] [PMID: 17914053]
- [69] Hung IFN, To KKW, Lee CK, *et al.* Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis* 2011; 52(4): 447-56. [http://dx.doi.org/10.1093/cid/ciq106] [PMID: 21248066]
- [70] Ko JH, Seok H, Cho SY, *et al.* Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. *Antivir Ther* 2018; 23(7): 617-22. [http://dx.doi.org/10.3851/IMP3243] [PMID: 29923831]
- [71] Duan K, Liu B, Li C, *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci USA* 2020; 117(17): 9490-6. [http://dx.doi.org/10.1073/pnas.2004168117] [PMID: 32253318]
- [72] Shakoory B, Carcillo JA, Chatham WW, *et al.* Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial. *Crit Care Med* 2016; 44(2): 275-81. [http://dx.doi.org/10.1097/CCM.0000000000001402] [PMID: 26584195]
- [73] Acute S, Syndrome R. OUP accepted manuscript. *Rheumatology* 2020; 19-21 [http://dx.doi.org/10.1093/rheumatology/keaa318]
- [74] Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *J Autoimmun* 2020; 111: 102452. [http://dx.doi.org/10.1016/j.jaut.2020.102452] [PMID: 32291137]
- [75] Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020; 395(10229): 1054-62. [http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]

- [76] Sciascia S, Aprà F, Baffa A, *et al.* Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp Rheumatol* 2020; 38(3): 529-32. [PMID: 32359035]
- [77] Ranieri VM, Pettilä V, Karvonen MK, *et al.* Effect of intravenous interferon β -1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: A randomized clinical trial. *JAMA* 2020; 323(8): 725-33. [http://dx.doi.org/10.1001/jama.2019.22525] [PMID: 32065831]
- [78] Bauer DC, Tay AP, Wilson LOW, *et al.* Supporting pandemic response using genomics and bioinformatics: A case study on the emergent SARS-CoV-2 outbreak. *Transbound Emerg Dis* 2020; 67(4): 1453-62. [http://dx.doi.org/10.1111/tbed.13588] [PMID: 32306500]
- [79] Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Saha RP, Lee SS. Extensive partnership, collaboration, and teamwork is required to stop the COVID-19 outbreak. *Arch Med Res* 2020; 51(7): 728-30. [http://dx.doi.org/10.1016/j.arcmed.2020.05.021] [PMID: 32532523]
- [80] Coronavirus T, Genomics DC. - An integrated national scale SARS-CoV-2 genomic surveillance network. *Lancet Microbe* 2020; 2019: 2019-20. [http://dx.doi.org/10.1016/S2666-5247(20)30054-9]
- [81] Li X, Yu J, Zhang Z, *et al.* Network bioinformatics analysis provides insight into drug repurposing for COVID-2019 journals 2020. [http://dx.doi.org/10.20944/journals202003.0286.v1]
- [82] Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov* 2020; 6 [http://dx.doi.org/10.1038/s41421-020-0153-3]
- [83] Messina F, Giombini E, Agrati C, *et al.* COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. *J Transl Med* 2020; 18(1): 233. [http://dx.doi.org/10.1186/s12967-020-02405-w] [PMID: 32522207]
- [84] Guzzi PH, Mercatelli D, Ceraolo C, Giorgi FM. Master regulator analysis of the SARS-CoV-2/human interactome. *J Clin Med* 2020; 9(4): 982. [http://dx.doi.org/10.3390/jcm9040982] [PMID: 32244779]
- [85] Yang ZH, Yan HF, Lin-Wang MRH. Screening key target genes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on bioinformatics and gene network. *Precis Med Res* 2020; 2: 48-55. [http://dx.doi.org/10.12032/PMR201900027]
- [86] Kumar N, Mishra B, Mehmood A, Athar M, Mukhtar MS. Integrative network biology framework elucidates molecular mechanisms of SARS-CoV-2 pathogenesis. *SSRN* 2020. [http://dx.doi.org/10.2139/ssrn.3581857]
- [87] Shiek A, Paramasivam P, Raj K, Kumar V. Interplay of host regulatory network on SARS-CoV-2 binding and replication machinery bioRxiv 2020. [http://dx.doi.org/10.1101/2020.04.20.050138]
- [88] Li X, Yu J, Zhang Z, *et al.* Network bioinformatics analysis provides insight into drug repurposing for COVID-19. *Med Drug Discov* 2021; 10: 100090. [http://dx.doi.org/10.1016/j.medidd.2021.100090] [PMID: 33817623]
- [89] Auwal MR, Rahman MR, Gov E, Shahjaman M, Moni MA. Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19. *Brief Bioinform* 2021; 22(5): bbab120. [http://dx.doi.org/10.1093/bib/bbab120] [PMID: 33839760]
- [90] Kumar R, Verma H, Singhvi N, *et al.* Comparative genomic analysis of rapidly evolving SARS CoV-2 viruses reveal mosaic pattern of phylogeographical distribution. bioRxiv 2020. [http://dx.doi.org/10.1101/2020.03.25.006213]
- [91] Shen Z, Xiao Y, Kang L, *et al.* Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients 2020; 1-27.
- [92] Armero A, Berthet N, Avarre J-C. Intra-host diversity of SARS-Cov-2 should not be neglected: case of the State of Victoria, Australia. *Viruses* 2021; 13(1): 133. [http://dx.doi.org/10.3390/v13010133] [PMID: 33477885]
- [93] Wang Y, Wang D, Zhang L, *et al.* Intra-host variation and evolutionary dynamics of SARS-CoV-2 populations in COVID-19 patients. *Genome Med* 2021; 13(1): 30. [http://dx.doi.org/10.1186/s13073-021-00847-5] [PMID: 33618765]
- [94] Graudenzi A, Maspero D, Angaroni F, Piazza R, Ramazzotti D. Mutational signatures and heterogeneous host response revealed *via* large-scale characterization of SARS-CoV-2 genomic diversity. *iScience* 2021; 24(2): 102116. [http://dx.doi.org/10.1016/j.isci.2021.102116] [PMID: 33532709]
- [95] Yin C. Genotyping coronavirus SARS-CoV-2: methods and implications. *Genomics* 2020; 112(5): 3588-96. [http://dx.doi.org/10.1016/j.ygeno.2020.04.016] [PMID: 32353474]
- [96] Pachetti M, Marini B, Benedetti F, *et al.* Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. *J Transl Med* 2020; 18(1): 179. [http://dx.doi.org/10.1186/s12967-020-02344-6] [PMID: 32321524]
- [97] Benvenuto D, Angeletti S, Giovanetti M, *et al.* Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. *J Infect* 2020; 81(1): e24-7. [http://dx.doi.org/10.1016/j.jinf.2020.03.058] [PMID: 32283146]
- [98] Lokman SM, Rasheduzzaman M, Salauddin A, *et al.* Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach. *Infect Genet Evol* 2020; 84: 104389. [http://dx.doi.org/10.1016/j.meegid.2020.104389] [PMID: 32502733]
- [99] Phan T. Genetic diversity and evolution of SARS-CoV-2. *Infect Genet Evol* 2020; 81: 104260. [http://dx.doi.org/10.1016/j.meegid.2020.104260] [PMID: 32092483]
- [100] Farkas C, Fuentes-Villalobos F, Garrido JL, Haigh J, Barria MI. Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions. *PeerJ* 2020; 8: e9255. [http://dx.doi.org/10.7717/peerj.9255] [PMID: 32509472]
- [101] Karmakar S, Kumar S, Katiyar V. Comparative Domain-fold analysis of the SARS-CoV-2 ORF1ab polyprotein: Insight into co-evolution, conservation of folding patterns, potential therapeutic strategies, and the possibility of reemergence. 2020; 1-34. [http://dx.doi.org/10.20944/journals202004.0286.v1]
- [102] Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. *Nat Med* 2020; 26(4): 450-2. [http://dx.doi.org/10.1038/s41591-020-0820-9] [PMID: 32284615]
- [103] Boni MF, Lemey P, Jiang X, *et al.* Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic bioRxiv 2020. [http://dx.doi.org/10.1101/2020.03.30.015008]
- [104] Tang X, Wu C, Li X, *et al.* On the origin and continuing evolution of SARS-CoV-2. *Natl Sci Rev* 2020; 7(6): 1012-23. [http://dx.doi.org/10.1093/nsr/nwaa036] [PMID: 34676127]
- [105] Yang H-C, Chen C, Wang J-H, *et al.* Genomic, geographic and temporal distributions of SARS-CoV-2 mutations bioRxiv 2020. [http://dx.doi.org/10.1101/2020.04.22.055863]
- [106] Zhu Z, Liu G, Meng K, Yang L, Meng G, Bioinformatics V. Rapid spread of mutant alleles in worldwide COVID-19 strains revealed by genome-wide SNP analysis current status: Posted subject areas. 2020; 1-19. [http://dx.doi.org/10.21203/rs.3.rs-23205/v1]
- [107] Guan Q, Sadykov M, Nugmanova R, Carr MJ, Arold ST, Pain A. The genomic variation landscape of globally-circulating clades of SARS-CoV-2 defines a genetic barcoding scheme bioRxiv 2020. [http://dx.doi.org/10.1101/2020.04.21.054221]
- [108] Wu A, Niu P, Wang L, *et al.* Mutations, recombination and insertion in the evolution of 2019-nCoV bioRxiv 2020. [http://dx.doi.org/10.1101/2020.02.29.971101]
- [109] Yarmarkovich M, Warrington JM, Farrel A, Maris JM. Identification of SARS-CoV-2 vaccine epitopes predicted to induce long-term population-scale immunity. *Cell Reports Med* 2020; 1(3): 100036. [http://dx.doi.org/10.1016/j.xcrm.2020.100036] [PMID: 32835302]
- [110] Vita R, Mahajan S, Overton JA, *et al.* The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Res* 2019; 47(D1): D339-43. [http://dx.doi.org/10.1093/nar/gky1006] [PMID: 30357391]
- [111] Pickett BE, Sadat EL, Zhang Y, *et al.* ViPR: an open bioinformatics database and analysis resource for virology research. *Nucleic Acids Res* 2012; 40(Database issue): D593-8. [http://dx.doi.org/10.1093/nar/gkr859] [PMID: 22006842]
- [112] Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. *Cell Host Microbe* 2020; 27(4): 671-680.e2. [http://dx.doi.org/10.1016/j.chom.2020.03.002] [PMID: 32183941]
- [113] Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. *Nucleic Acids Res* 2017; 45(W1): W24-9. [http://dx.doi.org/10.1093/nar/gkx346] [PMID: 28472356]
- [114] Bhattacharya M, Sharma AR, Patra P, *et al.* Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. *J Med Virol* 2020; 92(6):

- 618-31.
[http://dx.doi.org/10.1002/jmv.25736] [PMID: 32108359]
- [115] Campbell KM, Steiner G, Wells DK, Ribas A, Kalbasi A. Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.03.30.016931]
- [116] Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. *Viruses* 2020; 12(3): E254.
[http://dx.doi.org/10.3390/v12030254] [PMID: 32106567]
- [117] ter Meulen J, van den Brink EN, Poon LLM, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS Med* 2006; 3(7): e237.
[http://dx.doi.org/10.1371/journal.pmed.0030237] [PMID: 16796401]
- [118] Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* (80-) 2020; 368: 630-3.
[http://dx.doi.org/10.1126/science.abb7269]
- [119] Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. *Cell Mol Immunol* 2020; 17(5): 536-8.
[http://dx.doi.org/10.1038/s41423-020-0385-z] [PMID: 32132669]
- [120] Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science* (80-) 2020; 368: 1274-8.
[http://dx.doi.org/10.1126/science.abc2241]
- [121] Kang S, Yang M, Hong Z, et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. *Acta Pharm Sin B* 2020; 10(7): 1228-38.
[http://dx.doi.org/10.1016/j.apsb.2020.04.009] [PMID: 32363136]
- [122] Ye Q, West AMV, Silletti S, Corbett KD. Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.05.17.100685]
- [123] Jin Z, Du X, Xu Y, et al. Structure of M^{pro} from SARS-CoV-2 and discovery of its inhibitors. *Nature* 2020; 582(7811): 289-93.
[http://dx.doi.org/10.1038/s41586-020-2223-y] [PMID: 32272481]
- [124] Jin Z, Zhao Y, Sun Y, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. *Nat Struct Mol Biol* 2020; 27(6): 529-32.
[http://dx.doi.org/10.1038/s41594-020-0440-6] [PMID: 32382072]
- [125] Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors. *Science* (80-) 2020; 368: 368-412.
[http://dx.doi.org/10.1126/science.abb3405]
- [126] Dai W, Zhang B, Su H, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. *Science* (80) 2020.
[http://dx.doi.org/10.1126/science.abb4489]
- [127] Rut W, Zmudzinski M, Lyu Z, et al. Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.04.29.068890]
- [128] Kim Y, Jedrzejczak R, Maltseva NI, et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. *Protein Sci* 2020; 29(7): 1596-605.
[http://dx.doi.org/10.1002/pro.3873] [PMID: 32304108]
- [129] Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 2020; 581(7807): 215-20.
[http://dx.doi.org/10.1038/s41586-020-2180-5] [PMID: 32225176]
- [130] Wang Q, Zhang Y, Wu L, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell* 2020; 181(4): 894-904.e9.
[http://dx.doi.org/10.1016/j.cell.2020.03.045] [PMID: 32275855]
- [131] Fernandes Mariana S, et al. Insights on 3D structures of potential drug-targeting proteins of SARS-CoV-2: application of cavity search and molecular docking. *Molecular Informatics* 2021; 40.2, 2000096.
[http://dx.doi.org/10.1002/minf.202000096]
- [132] Pinto D, Park Y-J, Beltramello M, Walls AC, M. Alejandra Tortorici, Siro Bianchi, Stefano Jacomi, Katja Culap, Fabrizia Zatta, Anna De Marco, Alessia Peter, Barbara Guarini, Roberto Spreafico, Elisabetta Camerini, James Brett Case, D.V. and D.C. Structural and functional analysis of a potent sarbecovirus neutralizing 1 antibody bioRxiv 2020.
- [133] Loganathan SK, Schleicher K, Malik A, et al. Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling. *Science* 2020; 367(6483): 1264-9.
[http://dx.doi.org/10.1126/science.aaa0902] [PMID: 32165588]
- [134] Kopp M, Hsu A, Borgnia M, Parks R, Haynes BF. Controlling the SARS-CoV-2 spike glycoprotein conformation bioRxiv 2020.
- [135] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veerler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 2020; 181(2): 281-292.e6.
[http://dx.doi.org/10.1016/j.cell.2020.02.058] [PMID: 32155444]
- [136] Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* 2020; 369(6506): 1010-4.
[http://dx.doi.org/10.1126/science.abd0827] [PMID: 32540901]
- [137] Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science* (80-) 2020.
[http://dx.doi.org/10.1126/science.abb7498]
- [138] Peng Q, Peng R, Yuan B, et al. Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2. *Cell Rep* 2020; 31(11): 107774.
[http://dx.doi.org/10.1016/j.celrep.2020.107774] [PMID: 32531208]
- [139] Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science* (80-) 2020; 1560.
[http://dx.doi.org/10.1126/science.abc1560]
- [140] Lubin JH, Zardecki C, Dolan EM, et al. Evolution of the SARS-CoV-2 proteome in three dimensions (3D) during the first six months of the COVID-19 pandemic bioRxiv 2020.
- [141] Croll TI, Williams CJ, Chen VB, Richardson DC, Richardson JS. Improving SARS-CoV-2 structures: Peer review by early coordinate release. *Biophys J* 2021; 120(6): 1085-96.
[http://dx.doi.org/10.1016/j.bpj.2020.12.029] [PMID: 33460600]
- [142] Senior AW, Evans R, Jumper J, et al. Improved protein structure prediction using potentials from deep learning. *Nature* 2020; 577(7792): 706-10.
[http://dx.doi.org/10.1038/s41586-019-1923-7] [PMID: 31942072]
- [143] Flower TG, Hurley JH. Crystallographic molecular replacement using an *in silico*-generated search model of SARS-CoV-2 ORF8. *Protein Sci* 2021; 30(4): 728-34.
[http://dx.doi.org/10.1002/pro.4050] [PMID: 33625752]
- [144] Pandey P, Prasad K, Prakash A, Kumar V. Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: *in silico* binding mechanistic analysis. *J Mol Med (Berl)* 2020; 98(12): 1659-73.
[http://dx.doi.org/10.1007/s00109-020-01980-1] [PMID: 32965508]
- [145] Heo L, Feig M. Modeling of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins by machine learning and physics-based refinement bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.03.25.008904]
- [146] Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. *viruses* 2020; 12(2): 1-8.
[http://dx.doi.org/10.3390/v12020135] [PMID: 31991541]
- [147] Borkotoky S, Banerjee M. A computational prediction of SARS-CoV-2 structural protein inhibitors from *Azadirachta indica* (Neem). *J Biomol Struct Dyn* 2020.
[http://dx.doi.org/10.1080/07391102.2020.1774419] [PMID: 32462988]
- [148] Hall DC Jr, Ji HF. A search for medications to treat COVID-19 *via in silico* molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. *Travel Med Infect Dis* 2020; 35: 101646.
[http://dx.doi.org/10.1016/j.tmaid.2020.101646] [PMID: 32294562]
- [149] Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B* 2020; 10(5): 766-88.
[http://dx.doi.org/10.1016/j.apsb.2020.02.008] [PMID: 32292689]
- [150] Feng S, Luan X, Yifei Wang, Hui Wang, Z.Z.; Yiyang Wang, Zhuang Tian, Meixi Liu, Ying Xiao, Y.Z.; Ruilin Zhou, S.Z. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein. *Infect Genet Evol* 2020.
[http://dx.doi.org/10.1016/j.meegid.2020.104419]
- [151] Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life Sci J* 2020; 248: 117477.
[http://dx.doi.org/10.1016/j.lfs.2020.117477] [PMID: 32119961]
- [152] Mirza MU, Froeyen M. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. *J Pharm Anal* 2020; 10(4): 320-8.

- [153] Selvaraj C, Dinesh DC, Panwar U, Abhirami R, Boura E, Singh SK. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19. *J Biomol Struct Dyn* 2020. [http://dx.doi.org/10.1016/j.jbpha.2020.04.008] [PMID: 32346490]
- [154] Hussain M, Shabbir S, Amanullah A, Raza F, Imdad MJ, Zahid S. Immunoinformatic analysis of structural and epitope variations in the spike and Orf8 proteins of SARS-CoV-2/B.1.1.7. *J Med Virol* 2021; 93(7): 4461-8. [http://dx.doi.org/10.1002/jmv.26931] [PMID: 33704818]
- [155] Cai Y, Zhang J, Xiao T, *et al.* Distinct conformational states of SARS-CoV-2 spike protein. *Science* (80-) 2020; 369: 1586-92.
- [156] Kumar A, Pandey SN, Pareek V, Narayan RK, Faiq MA, Kumari C. Predicting susceptibility for SARS-CoV-2 infection in domestic and wildlife animals using ACE2 protein sequence homology. *Zoo Biol* 2021; 40(1): 79-85. [http://dx.doi.org/10.1002/zoo.21576] [PMID: 33034084]
- [157] Das S, Sarmah S. S.L.& A.S.R. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. *J Biomol Struct Dyn* 2020. [http://dx.doi.org/10.1080/07391102.2020.1763201] [PMID: 32362245]
- [158] Mothay D, Ramesh KV. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock. *Virusdisease* 2020; 1-6. [http://dx.doi.org/10.1007/s13337-020-00585-z] [PMID: 32363219]
- [159] Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. *Life Sci J* 2020; 251: 117627. [http://dx.doi.org/10.1016/j.lfs.2020.117627] [PMID: 32251634]
- [160] Ortega JT, Serrano ML, Pujol FH, Rangel HR. Unrevealing sequence and structural features of novel coronavirus using *in silico* approaches: The main protease as molecular target. *EXCLI J* 2020; 19: 400-9. [http://dx.doi.org/10.17179/excli2020-1189] [PMID: 32210741]
- [161] Islam R, Parves R, Paul AS, *et al.* A Molecular Modeling Approach to Identify Effective Antiviral Phytochemicals against the Main Protease of SARS-CoV-2. *J Biomol Struct Dyn* 2020; 1-20. [http://dx.doi.org/10.1080/07391102.2020.1761883] [PMID: 32340562]
- [162] Sinha SK, Shakya A, Prasad SK, *et al.* An *in-silico* evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. *J Biomol Struct Dyn* 2020; 1-13. [http://dx.doi.org/10.1080/07391102.2020.1762741] [PMID: 32345124]
- [163] Sukanth Kumar Enmozhi, Kavitha Raja, I.S.& J. Joseph Andrographolide As a Potential Inhibitor of SARS-CoV-2 Main Protease: An *in silico* approach. *J Biomol Struct Dyn* 2020; 1-10. [http://dx.doi.org/10.1080/07391102.2020.1866669]
- [164] Lung J, Lin YS, Yang YH, *et al.* The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. *J Med Virol* 2020; 92(6): 693-7. [http://dx.doi.org/10.1002/jmv.25761] [PMID: 32167173]
- [165] Mustatab WH, Sajjad A, Wajid AS. Stilbene-based Natural Compounds as Promising Drug Candidates against COVID-19. *J Biomol Struct Dyn* 2020. [http://dx.doi.org/10.1080/07391102.2020.1762743] [PMID: 32345140]
- [166] Gupta MK, Vemula S, Donde R, Gouda G, Behera L, Vadde R. *In-silico* approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. *J Biomol Struct Dyn* 2020; 1-11. [http://dx.doi.org/10.1080/07391102.2020.1837679] [PMID: 32238078]
- [167] Sarma P, Sekhar N, Prajapat M, *et al.* *In-silico* homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). *J Biomol Struct Dyn* 2020. [http://dx.doi.org/10.1080/07391102.2020.1753580] [PMID: 32266867]
- [168] Lipkowitz KB, Cundari TR, Boyd DB, Eds. Reviews in computational chemistry. John Wiley & Sons 2008.
- [169] Novikov FN, Chilov GG. Molecular docking : theoretical background, practical applications and perspectives 2009; 237-42. [http://dx.doi.org/10.1016/j.mencom.2009.09.001]
- [170] Erickson JA, Jalaie M, Robertson DH, Lewis RA, Vieth M. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. *J Med Chem* 2004; 47(1): 45-55. [http://dx.doi.org/10.1021/jm030209y] [PMID: 14695819]
- [171] aLindner HA, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T, Ménard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. *J Virol* 2005; 79(24): 15199-208. [http://dx.doi.org/10.1128/JVI.79.24.15199-15208.2005] [PMID: 16306591]
- [172] Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. *J Biomol Struct Dyn* 2020; 0: 1-6. [http://dx.doi.org/10.1080/07391102.2020.1752802] [PMID: 32248766]
- [173] Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A. Rapid identification of potential inhibitors of SARS CoV 2 main protease by deep docking of 1.3 billion compounds. *Mol Inform* 2020; 39(8): e2000028. [http://dx.doi.org/10.1002/minf.202000028] [PMID: 32162456]
- [174] Abdelsattar AS, Dawoud A, Helal MA. Interaction of nanoparticles with biological macromolecules: a review of molecular docking studies. *Nanotoxicology* 2020; 1-30. [PMID: 33283572]
- [175] Attia GH, Moemen YS, Youns M, Ibrahim AM, Abdou R, El Raey MA. Antiviral zinc oxide nanoparticles mediated by hesperidin and *in silico* comparison study between antiviral phenolics as anti-SARS-CoV-2. *Colloids Surf B Biointerfaces* 2021; 203: 111724. [http://dx.doi.org/10.1016/j.colsurfb.2021.111724] [PMID: 33838582]
- [176] Farouq MAH, Al Qaraghuli MM, Kubiak-Ossowska K, Ferro VA, Mulheran PA. Biomolecular interactions with nanoparticles: applications for coronavirus disease 2019. *Curr Opin Colloid Interface Sci* 2021; 54: 101461. [http://dx.doi.org/10.1016/j.cocis.2021.101461] [PMID: 33907504]
- [177] Mitra S, Mukhopadhyay BC, Biswas SR. Potential application of the nisin Z preparation of *Lactococcus lactis* W8 in preservation of milk. *Lett Appl Microbiol* 2011; 53(1): 98-105. [http://dx.doi.org/10.1111/j.1472-765X.2011.03075.x] [PMID: 21554339]
- [178] Bhattacharya R, Gupta AM, Mitra S, Mandal S, Biswas SR. A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2. *Virology* 2021; 552: 107-11. [http://dx.doi.org/10.1016/j.virol.2020.10.002] [PMID: 33130382]
- [179] Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration. *Biochem Biophys Res Commun* 2021; 554: 94-8. [http://dx.doi.org/10.1016/j.bbrc.2021.03.100] [PMID: 33789211]
- [180] Tavassoly O, Safavi F, Tavassoly I. Seeding brain protein aggregation by SARS-CoV-2 as a possible long-term complication of COVID-19 infection. *ACS Chem Neurosci* 2020; 11(22): 3704-6. [http://dx.doi.org/10.1021/acscchemneuro.0c00676] [PMID: 33147014]
- [181] Alsulami AF, Thomas SE, Jamasb AR, *et al.* SARS-CoV-2 3D database: Understanding the coronavirus proteome and evaluating possible drug targets. *Brief Bioinform* 2021; 22(2): 769-80. [http://dx.doi.org/10.1093/bib/bbaa404] [PMID: 33416848]
- [182] Saeed M, Saeed A, Alam MJ, Alreshidi M. Receptor-based pharmacophore modeling in the search for natural products for COVID-19 M^{pro}. *Molecules* 2021; 26(6): 1549. [http://dx.doi.org/10.3390/molecules26061549] [PMID: 33799871]
- [183] Rampogu S, Lee KW. Pharmacophore modelling-based drug repurposing approaches for SARS-CoV-2 therapeutics. *Front Chem* 2021; 9: 636362. [http://dx.doi.org/10.3389/fchem.2021.636362] [PMID: 34041221]
- [184] Idris MO, Yekeen AA, Alakanse OS, Durojaye OA. Computer-aided screening for potential TMPRSS2 inhibitors: a combination of

- pharmacophore modeling, molecular docking and molecular dynamics simulation approaches. *J Biomol Struct Dyn* 2020; 1-19. [PMID: 32672528]
- [185] Tejera E, Munteanu CR, López-Cortés A, Cabrera-Andrade A, Pérez-Castillo Y. Drugs repurposing using QSAR, docking and molecular dynamics for possible inhibitors of the SARS-CoV-2 M^{pro} protease. *Molecules* 2020; 25(21): E5172. [http://dx.doi.org/10.3390/molecules25215172] [PMID: 33172092]
- [186] Alves VM, Bobrowski T, Melo-Filho CC, *et al.* QSAR modeling of SARS-CoV M^{pro} inhibitors identifies sifugolix, cenicriviroc, proglumetacin, and other drugs as candidates for repurposing against SARS-CoV-2. *Mol Inform* 2021; 40(1): e2000113. [http://dx.doi.org/10.1002/minf.202000113] [PMID: 33405340]
- [187] Amin SA, Ghosh K, Gayen S, Jha T. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some. *J Biomol Struct Dyn* 2020; 1-10. [PMID: 32568618]
- [188] Si Y, Xu X, Hu Y, Si H, Zhai H. Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19. *Chem Biol Drug Des* 2021; 97(4): 978-83. [http://dx.doi.org/10.1111/cbdd.13822] [PMID: 33386649]
- [189] Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT. *In silico* methods for drug repurposing and pharmacology. *Wiley Interdiscip Rev Syst Biol Med* 2016; 8(3): 186-210. [http://dx.doi.org/10.1002/wsbm.1337] [PMID: 27080087]
- [190] Jenwithesuk E, Horst JA, Rivas KL, *et al.* Novel paradigms for drug discovery: computational multitarget screening 2008; 29: 62-71. [http://dx.doi.org/10.1016/j.tips.2007.11.007]
- [191] Helal MA, Avery MA. Combined receptor-based and ligand-based approach to delineate the mode of binding of guaianolide-endoperoxides to PfATP6. *Bioorg Med Chem Lett* 2012; 22(17): 5410-4. [http://dx.doi.org/10.1016/j.bmcl.2012.07.053] [PMID: 22877631]
- [192] Kirchmair J, Distinto S, Schuster D, Spitzer G, Langer T, Wolber G. Enhancing drug discovery through *in silico* screening: strategies to increase true positives retrieval rates. *Curr Med Chem* 2008; 15(20): 2040-53. [http://dx.doi.org/10.2174/092986708785132843] [PMID: 18691055]
- [193] Murgueitio MS, Bermudez M, Mortier J, Wolber G. *In silico* virtual screening approaches for anti-viral drug discovery. *Drug Discov Today Technol* 2012; 9(3): e219-25. [http://dx.doi.org/10.1016/j.ddtec.2012.07.009] [PMID: 24990575]
- [194] Nguyen TT, Ryu HJ, Lee SH, *et al.* Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and *in vitro* confirmation. *Bioorg Med Chem Lett* 2011; 21(10): 3088-91. [http://dx.doi.org/10.1016/j.bmcl.2011.03.034] [PMID: 21470860]
- [195] Sepay N, Sepay N, Al Hoque A, Mondal R, Halder UC, Muddassir M. *In silico* fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme. *Struct Chem* 2020; 1-10. [http://dx.doi.org/10.1007/s11224-020-01537-5] [PMID: 32412544]
- [196] Polli JE. *In vitro* studies are sometimes better than conventional human pharmacokinetic *in vivo* studies in assessing bioequivalence of immediate-release solid oral dosage forms. *AAPS J* 2008; 10(2): 289-99. [http://dx.doi.org/10.1208/s12248-008-9027-6] [PMID: 18500564]
- [197] Choy KT, Wong AYL, Kaewpreedee P, *et al.* Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication *in vitro*. *Antiviral Res* 2020; 178: 104786. [http://dx.doi.org/10.1016/j.antiviral.2020.104786] [PMID: 32251767]
- [198] Wang M, Cao R, Zhang L, *et al.* Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*. *Cell Res* 2020; 30(3): 269-71. [http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
- [199] Grein J, Ohmagari N, Shin D, *et al.* Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med* 2020; 382(24): 2327-36. [http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
- [200] Wang Y, Zhang D, Du G, *et al.* Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; 395(10236): 1569-78. [http://dx.doi.org/10.1016/S0140-6736(20)31022-9] [PMID: 32423584]
- [201] Tu YF, Chien CS, Yarmishyn AA, *et al.* A review of sars-cov-2 and the ongoing clinical trials. *Int J Mol Sci* 2020; 21(7): E2657. [http://dx.doi.org/10.3390/ijms21072657] [PMID: 32290293]
- [202] Lambe T, Spencer A, Belij-Rammerstorfer S, *et al.* ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques Neeltje van Doremalen. [http://dx.doi.org/10.1101/2020.05.13.093195]
- [203] Takayama K. *In vitro* and animal models for SARS-CoV-2 research. *Trends Pharmacol Sci* 2020; 41(8): 513-7. [http://dx.doi.org/10.1016/j.tips.2020.05.005] [PMID: 32553545]
- [204] Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. *Trends Pharmacol Sci* 2020; 41(6): 363-82. [http://dx.doi.org/10.1016/j.tips.2020.03.006] [PMID: 32291112]
- [205] Shi J, Yubo X. Challenges of drug development during the COVID-19 pandemic : key considerations for clinical trial designs Peer Review Status : Challenges of drug development during the COVID-19 pandemic : key considerations for clinical trial designs. 2020; 0-16. [http://dx.doi.org/10.22541/au.158705386.69295078]